Clonal Cytopenia of Undetermined Significance Clinical Trial
Official title:
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05102370 -
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
|
Phase 1 | |
| Recruiting |
NCT04102423 -
CHIP/CCUS Natural History Protocol
|
||
| Recruiting |
NCT03418038 -
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02958462 -
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
|
N/A | |
| Recruiting |
NCT05641831 -
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
|
Phase 2 | |
| Recruiting |
NCT05483010 -
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04902833 -
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
|
||
| Not yet recruiting |
NCT06240754 -
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
|
Phase 2 | |
| Not yet recruiting |
NCT06063486 -
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
|
Phase 2 |